Sampo plc
11.3.2025 08:30:00 CET | Globenewswire | Press release
Sampo is introducing new reporting segments and publishes restated key figures for 2023 and 2024
Sampo is introducing new reporting segments and publishes restated key figures for 2023 and 2024
Sampo plc, stock exchange release, 11 March 2025 at 9:30 am EET
Sampo is introducing new reporting segments and publishes restated key figures for 2023 and 2024
Sampo is introducing new reporting segments to reflect its transformation into a fully-integrated P&C insurance group following the acquisition of Topdanmark in 2024.
As of the first quarter of 2025, Sampo will report its financial performance in the following segments based on the Group’s operational business areas:
- Private will include the Group’s Nordic private customer business, previously reported under the If and Topdanmark segments in Sampo’s accounts. The segment would have represented 44 per cent of the Group’s insurance revenue in 2024.
- Commercial will include the Group’s Nordic commercial customer businesses, previously reported under the If and Topdanmark segments in Sampo’s accounts, as well as Oona Health. The segment would have represented 25 per cent of the Group’s insurance revenue in 2024.
- Industrial will include the Group’s Nordic Industrial customer business, previously reported under the If segment in Sampo’s accounts. Corporates with revenues of more than SEK 500 million, or more than 500 employees, are classified as Industrial customers. The segment would have represented 8 per cent of the Group’s insurance revenue in 2024.
- UK will include the Group’s UK business, previously reported as Hastings in Sampo’s accounts. The segment would have represented 20 per cent of the Group’s insurance revenue in 2024.
In addition to the 4 main reporting segments, the underwriting result will include Other operations, encompassing the Group’s Baltic business, group eliminations and other internal items (representing 3 per cent of the Group’s insurance revenue in 2024).
In each segment, Sampo will report the key P&L figures from gross written premiums to the underwriting result. P&L figures below the underwriting result, such as net investment income and insurance finance income or expense, will be disclosed at the group level and described in a separate text section in the Group’s financial reports.
The new segmentation does not affect Sampo’s reported group level P&L figures or financial targets for 2024-2026. However, as of the first quarter of 2025, Sampo will disclose its underlying margin development based on its Nordic operations, rather than a group level.
The restated key figures for full-years 2023 and 2024 as well as for each quarter of 2024 are attached to this release and available at www.sampo.com/analyst-materials. Also, a short presentation regarding the segmentation is attached to this release.
SAMPO PLC
Investor Relations and Group Communications
For further information, please contact:
Sami Taipalus
Head of Investor Relations
tel. +358 10 516 0030
Maria Silander
Communications Manager, Media Relations
tel. +358 10 516 0031
Distribution:
Nasdaq Helsinki
Nasdaq Stockholm
Nasdaq Copenhagen
London Stock Exchange
FIN-FSA
The principal media
www.sampo.com
Attachments
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Chery Group18.4.2026 15:54:00 CEST | Press release
iCAUR V27 Secures CATARC L3 Off-Road Certification, Solidifying Its New Energy Off-Road Capability with Robust Technology
Sanofi Winthrop Industrie18.4.2026 12:00:00 CEST | Press release
Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study
Organizing Committee of the 2026 Fujian Provincial Conference on the Development of Cultural and Tourism Economy18.4.2026 06:50:27 CEST | Press release
2026 Fujian Provincial Conference on Development of Cultural, Tourism Economy opens on Apr. 17 in Zhangzhou, SE China's Fujian
Evaxion17.4.2026 21:10:00 CEST | Press release
Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial
Zymeworks Inc.17.4.2026 21:00:00 CEST | Press release
Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom